A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018

Willis, Gabriela A., Mayfield, Helen J., Kearns, Therese, Naseri, Take, Thomsen, Robert, Gass, Katherine, Sheridan, Sarah, Graves, Patricia M., and Lau, Colleen L. (2020) A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018. PLoS Neglected Tropical Diseases, 14 (11). e0008854.

Preview

PDF (Published Version) - Published Version
Available under License Creative Commons Attribution.
Download (1MB) | Preview

DOI: 10.1371/journal.pntd.0008854

View at Publisher Website: https://doi.org/10.1371/journal.pntd.000...

861

Abstract

The Global Programme to Eliminate Lymphatic Filariasis has made considerable progress but is experiencing challenges in meeting targets in some countries. Recent World Health Organization guidelines have recommended two rounds of triple-drug therapy with ivermectin, diethylcarbamazine (DEC), and albendazole (IDA), in areas where mass drug administration (MDA) results with two drugs (DEC and albendazole) have been suboptimal, as is the case in Samoa. In August 2018, Samoa was the first country in the world to implement countrywide triple-drug MDA. This paper aims to describe Samoa’s experience with program coverage and adverse events (AEs) in the first round of triple-drug MDA. We conducted a large cross-sectional community survey to assess MDA awareness, reach, compliance, coverage and AEs in September/October 2018, 7–11 weeks after the first round of triple-drug MDA. In our sample of 4420 people aged ≥2 years (2.2% of the population), age-adjusted estimates indicated that 89.0% of the eligible population were offered MDA, 83.9% of the eligible population took MDA (program coverage), and 80.2% of the total population took MDA (epidemiological coverage). Overall, 83.8% (2986/3563) reported that they did not feel unwell at all after taking MDA. Mild AEs (feeling unwell but able to do normal everyday things) were reported by 13.3% (476/3563) and moderate or severe AEs (feeling unwell and being unable to do normal everyday activities such as going to work or school) by 2.9% (103/3563) of participants. This study following the 2018 triple-drug MDA in Samoa demonstrated a high reported program awareness and reach of 90.8% and 89.0%, respectively. Age-adjusted program coverage of 83.9% of the total population showed that MDA was well accepted and well tolerated by the community.


Item ID:	66293
Item Type:	Article (Research - C1)
ISSN:	1935-2735
Copyright Information:	© 2020 Willis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproductionin any medium, provided the original author and source are credited.
Funders:	Coalition for Operational Research on Neglected Tropical Diseases (CORNTD)
Date Deposited:	25 Feb 2021 02:45
FoR Codes:	42 HEALTH SCIENCES > 4202 Epidemiology > 420202 Disease surveillance @ 34% 45 INDIGENOUS STUDIES > 4516 Pacific Peoples health and wellbeing > 451605 Pacific Peoples epidemiology @ 33% 32 BIOMEDICAL AND CLINICAL SCIENCES > 3207 Medical microbiology > 320704 Medical parasitology @ 33%
SEO Codes:	20 HEALTH > 2001 Clinical health > 200104 Prevention of human diseases and conditions @ 50% 20 HEALTH > 2005 Specific population health (excl. Indigenous health) > 200599 Specific population health (excl. Indigenous health) not elsewhere classified @ 50%
Downloads:	Total: 861 Last 12 Months: 4
	More Statistics

Actions (Repository Staff Only)

Item Control Page